NasdaqGS - Delayed Quote • USD
Cogent Biosciences, Inc. (COGT)
At close: May 9 at 4:00 PM EDT
After hours: May 9 at 4:20 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 9 | 10 | 9 |
| Avg. Estimate | -0.53 | -0.53 | -2.12 | -2.09 |
| Low Estimate | -0.66 | -0.68 | -2.63 | -2.85 |
| High Estimate | -0.33 | -0.34 | -1.41 | -1.39 |
| Year Ago EPS | -0.59 | -0.64 | -2.42 | -2.12 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 8 | 8 |
| Avg. Estimate | -- | -- | -- | 1.32M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | 10.6M |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.54 | -0.5 | -0.56 | -0.52 |
| EPS Actual | -0.59 | -0.64 | -0.63 | -0.62 |
| Difference | -0.05 | -0.14 | -0.07 | -0.1 |
| Surprise % | -9.30% | -28.00% | -12.50% | -19.20% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.53 | -0.53 | -2.12 | -2.09 |
| 7 Days Ago | -0.49 | -0.5 | -2 | -1.99 |
| 30 Days Ago | -0.49 | -0.5 | -2 | -1.99 |
| 60 Days Ago | -0.49 | -0.5 | -2 | -1.99 |
| 90 Days Ago | -0.51 | -0.47 | -2.1 | -1.85 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | 1 |
| Up Last 30 Days | -- | -- | -- | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 5 | 5 | 5 | 5 |
Growth Estimates
| CURRENCY IN USD | COGT | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 10.20% | -- | -- | 8.60% |
| Next Qtr. | 17.20% | -- | -- | 11.90% |
| Current Year | 12.40% | -- | -- | 5.60% |
| Next Year | 1.40% | -- | -- | 13.20% |
| Next 5 Years (per annum) | -- | -- | -- | 11.07% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Needham: Buy to Buy | 5/8/2024 |
| Maintains | JP Morgan: Overweight to Overweight | 2/27/2024 |
| Maintains | Citigroup: Buy to Buy | 2/26/2024 |
| Downgrade | Baird: Outperform to Neutral | 2/26/2024 |
| Reiterates | Needham: Buy to Buy | 2/26/2024 |
| Maintains | Wedbush: Neutral to Neutral | 2/23/2024 |
Related Tickers
IRON Disc Medicine, Inc.
30.77
+4.87%
PHVS Pharvaris N.V.
20.57
-1.34%
DNTH Dianthus Therapeutics, Inc.
24.93
+4.70%
IMCR Immunocore Holdings plc
59.85
-2.40%
RARE Ultragenyx Pharmaceutical Inc.
41.22
-0.82%
VRDN Viridian Therapeutics, Inc.
13.91
-6.64%
TVTX Travere Therapeutics, Inc.
6.60
-3.23%
FDMT 4D Molecular Therapeutics, Inc.
25.64
-2.62%
MRSN Mersana Therapeutics, Inc.
2.4650
-27.50%
NUVL Nuvalent, Inc.
67.52
-0.03%